MCM
BIOA

MAI Capital Management’s BioAge Labs BIOA Stock Holding History

MAI Capital Management’s Portfolio BIOA Stock Details BIOA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$105 Buy
+6
New +$116 ﹤0.01% 4751

Other funds holding BIOA

ACM
AH Capital Management Menlo Park, California $1.29B AUM 26.81% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

MAI Capital Management's BIOA Position: Q1 2026 in Review

MAI Capital Management opened a new position in BioAge Labs (BIOA) in Q1 2026: 6 shares worth $105. The stake represents ﹤0.01% of the portfolio and ranks #4751 among its holdings.

144 funds tracked by Wall St. Rank hold BIOA as of Q1 2026.

  • MAI Capital Management held 6 shares of BioAge Labs worth $105 as of Q1 2026.
  • BioAge Labs was a new MAI Capital Management position in Q1 2026.
  • BioAge Labs made up ﹤0.01% of MAI Capital Management's portfolio in Q1 2026, its #4751 holding.
  • 144 funds tracked by Wall St. Rank held BioAge Labs as of Q1 2026.

Based on MAI Capital Management's 13F filing for Q1 2026, filed 15 May 2026.